ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0205

Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Abstract Number: 2623

Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Abstract Number: 0306

Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 1486

Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2
Abstract Number: 2026

Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 1328

Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study
Abstract Number: 0460

Cartilage Damage or (sub)luxation of Finger Joints: Impact on Physical Function in Patients with Rheumatoid Arthritis
Abstract Number: 0027

Cation Channel TRPC1 Regulates Mesenchymal Stem Cell Differentiation and Bone Formation
Abstract Number: 2379

Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus
Abstract Number: 2250

Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity
Abstract Number: 1149

Cause-Specific Proportionate Mortality Trends in Idiopathic Inflammatory Myopathies
Abstract Number: L18

CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis
Abstract Number: 0949

CCN1 Is a Novel Therapeutic Target for Reducing Structural Damage in Rheumatoid Arthritis: Demonstration from 2 Preclinical Models
Abstract Number: 2036

CCN6 Gene Mutation Induces Mitochondrial Dysfunction: The Cause of Progressive Pseudo-rheumatoid Dysplasia
Abstract Number: 0103

CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].